Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Conditions: Cutaneous T Cell Lymphoma; Fungoides Mycosis Sezary Syndrome Interventions: Drug: Pembrolizumab; Drug: Mogamulizumab Sponsors: University of Michigan Rogel Cancer Center; Merck Sharp & Dohme LLC; Hoosier Cancer Research Network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2023 Category: Research Source Type: clinical trials